Pazufloxacina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pazufloxacina" in Italian language version.

refsWebsite

Global rank Italian rank

16nih.gov

4^th place

9^th place

5doi.org

2^nd place

7^th place

3oadoi.org

799^th place

22^nd place

2jst.go.jp

1,903^rd place

3,782^nd place

2asm.org

3,555^th place

2,382^nd place

1oxfordjournals.org

1,389^th place

732^nd place

1medicaljournals.se

low place

asm.org

aac.asm.org

Muratani T, Inoue M, Mitsuhashi S, In vitro activity of T-3761, a new fluoroquinolone, in Antimicrobial Agents and Chemotherapy, vol. 36, n. 10, ottobre 1992, pp. 2293–303, PMC 245492, PMID 1332594. URL consultato il 14 ottobre 2014.
Tanaka M, Matsumoto T, Sakumoto M, Takahashi K, Saika T, Kabayashi I, Kumazawa J, Reduced clinical efficacy of pazufloxacin against gonorrhea due to high prevalence of quinolone-resistant isolates with the GyrA mutation. The Pazufloxacin STD Group, in Antimicrobial Agents and Chemotherapy, vol. 42, n. 3, marzo 1998, pp. 579–82, PMC 105501, PMID 9517935. URL consultato il 14 ottobre 2014.

doi.org

dx.doi.org

Higa F, Shinzato T, Toyama M, Haranaga S, Furugen M, Tateyama M, Kawakami K, Saito A, Efficacy of pazufloxacin mesilate in Legionnaires' disease: a case report and in vitro study of the isolate, in Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, vol. 11, n. 3, giugno 2005, pp. 164–8, DOI:10.1007/s10156-005-0381-3, PMID 15990982. URL consultato il 14 ottobre 2014.
Takahashi K, Muratani T, Akasaka S, Yamada Y, Matsumoto T, The efficacy of sequential therapy using pazufloxacin followed by oral fluoroquinolones for treatment of pyelonephritis, in Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, vol. 19, n. 3, giugno 2013, pp. 456–64, DOI:10.1007/s10156-012-0505-5, PMID 23188166. URL consultato il 14 ottobre 2014.
Hamada Y, Imaizumi H, Kobayashi M, Sunakawa K, Saigenji K, Yago K, Liver abscess that responded well to pazufloxacin therapy, in Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, vol. 12, n. 1, febbraio 2006, pp. 42–6, DOI:10.1007/s10156-005-0423-x, PMID 16506089. URL consultato il 14 ottobre 2014.
Higa F, Akamine M, Haranaga S, Tohyama M, Shinzato T, Tateyama M, Koide M, Saito A, Fujita J, In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species, in The Journal of Antimicrobial Chemotherapy, vol. 56, n. 6, dicembre 2005, pp. 1053–7, DOI:10.1093/jac/dki391, PMID 16260445. URL consultato il 14 ottobre 2014.
Sawada Y, Nakamura M, Tokura Y, Generalized fixed drug eruption caused by pazufloxacin, in Acta Dermato-venereologica, vol. 91, n. 5, settembre 2011, pp. 600–1, DOI:10.2340/00015555-1132, PMID 21597677. URL consultato il 14 ottobre 2014.

jst.go.jp

joi.jlc.jst.go.jp

Minami S, Hattori R, Matsuda A, [Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate], in Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica, vol. 122, n. 2, agosto 2003, pp. 161–78, PMID 12890902. URL consultato il 13 ottobre 2014.
Kakeya H, Ehara N, Fukushima K, Seki M, Izumikawa K, Yamamoto Y, Yanagihara K, Saito A, Kohno S, Severe Legionnaires' disease successfully treated using a combination of fluoroquinolone, erythromycin, corticosteroid, and sivelestat, in Internal Medicine (Tokyo, Japan), vol. 47, n. 8, 2008, pp. 773–7, PMID 18421197. URL consultato il 14 ottobre 2014.

medicaljournals.se

Sawada Y, Nakamura M, Tokura Y, Generalized fixed drug eruption caused by pazufloxacin, in Acta Dermato-venereologica, vol. 91, n. 5, settembre 2011, pp. 600–1, DOI:10.2340/00015555-1132, PMID 21597677. URL consultato il 14 ottobre 2014.

nih.gov

ncbi.nlm.nih.gov

Furuhata K, Hiraiwa T, Ono S, Tanaka K, Shimotori T, Makino S, Kitamura K, Aikawa Y, Izumi Y, Kimura T, [General pharmacology of T-3761, a new oral quinolone antibacterial agent (1). Effect on the central nervous system], in The Japanese Journal of Antibiotics, vol. 48, n. 5, maggio 1995, pp. 692–705, PMID 7637204.
Higa F, Shinzato T, Toyama M, Haranaga S, Furugen M, Tateyama M, Kawakami K, Saito A, Efficacy of pazufloxacin mesilate in Legionnaires' disease: a case report and in vitro study of the isolate, in Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, vol. 11, n. 3, giugno 2005, pp. 164–8, DOI:10.1007/s10156-005-0381-3, PMID 15990982. URL consultato il 14 ottobre 2014.
Minami S, Hattori R, Matsuda A, [Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate], in Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica, vol. 122, n. 2, agosto 2003, pp. 161–78, PMID 12890902. URL consultato il 13 ottobre 2014.
Johnson AP, Pazufloxacin Toyama Chemical Co, in Current Opinion in Investigational Drugs (London, England : 2000), vol. 1, n. 1, settembre 2000, pp. 52–7, PMID 11249595.
Muratani T, Inoue M, Mitsuhashi S, In vitro activity of T-3761, a new fluoroquinolone, in Antimicrobial Agents and Chemotherapy, vol. 36, n. 10, ottobre 1992, pp. 2293–303, PMC 245492, PMID 1332594. URL consultato il 14 ottobre 2014.
Nomura N, Mitsuyama J, Furuta Y, Yamada H, Nakata M, Fukuda T, Yamada H, Takahata M, Minami S, [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone], in The Japanese Journal of Antibiotics, vol. 55, n. 4, agosto 2002, pp. 412–39, PMID 12378871.
Wang XG, Miao J, Liang DR, Yu Q, Liang MZ, Zhang SH, [Clinical pharmacokinetics/pharmacodynamics study on pazufloxacin methanesulphonate injection], in Sichuan Da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition, vol. 40, n. 4, luglio 2009, pp. 689–93, PMID 19764574.
Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ, A critical review of the fluoroquinolones: focus on respiratory infections, in Drugs, vol. 62, n. 1, 2002, pp. 13–59, PMID 11790155.
Zhanel GG, Fontaine S, Adam H, Schurek K, Mayer M, Noreddin AM, Gin AS, Rubinstein E, Hoban DJ, A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections, in Treatments in Respiratory Medicine, vol. 5, n. 6, 2006, pp. 437–65, PMID 17154673.
Kodama Y, Hori S, Tominaga S, Ohwada A, Yoshimi K, Sekiya M, Yamazaki M, Mori T, Suzuki T, Fukuchi Y, Takahashi K, [Evaluation of clinical effectiveness of Pazufloxacin Mesilate in acute exacerbation of chronic respiratory diseases], in Nihon Kokyūki Gakkai Zasshi = the Journal of the Japanese Respiratory Society, vol. 46, n. 10, ottobre 2008, pp. 781–7, PMID 19044026.
Takahashi K, Muratani T, Akasaka S, Yamada Y, Matsumoto T, The efficacy of sequential therapy using pazufloxacin followed by oral fluoroquinolones for treatment of pyelonephritis, in Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, vol. 19, n. 3, giugno 2013, pp. 456–64, DOI:10.1007/s10156-012-0505-5, PMID 23188166. URL consultato il 14 ottobre 2014.
Hamada Y, Imaizumi H, Kobayashi M, Sunakawa K, Saigenji K, Yago K, Liver abscess that responded well to pazufloxacin therapy, in Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, vol. 12, n. 1, febbraio 2006, pp. 42–6, DOI:10.1007/s10156-005-0423-x, PMID 16506089. URL consultato il 14 ottobre 2014.
Tanaka M, Matsumoto T, Sakumoto M, Takahashi K, Saika T, Kabayashi I, Kumazawa J, Reduced clinical efficacy of pazufloxacin against gonorrhea due to high prevalence of quinolone-resistant isolates with the GyrA mutation. The Pazufloxacin STD Group, in Antimicrobial Agents and Chemotherapy, vol. 42, n. 3, marzo 1998, pp. 579–82, PMC 105501, PMID 9517935. URL consultato il 14 ottobre 2014.
Higa F, Akamine M, Haranaga S, Tohyama M, Shinzato T, Tateyama M, Koide M, Saito A, Fujita J, In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species, in The Journal of Antimicrobial Chemotherapy, vol. 56, n. 6, dicembre 2005, pp. 1053–7, DOI:10.1093/jac/dki391, PMID 16260445. URL consultato il 14 ottobre 2014.
Kakeya H, Ehara N, Fukushima K, Seki M, Izumikawa K, Yamamoto Y, Yanagihara K, Saito A, Kohno S, Severe Legionnaires' disease successfully treated using a combination of fluoroquinolone, erythromycin, corticosteroid, and sivelestat, in Internal Medicine (Tokyo, Japan), vol. 47, n. 8, 2008, pp. 773–7, PMID 18421197. URL consultato il 14 ottobre 2014.
Sawada Y, Nakamura M, Tokura Y, Generalized fixed drug eruption caused by pazufloxacin, in Acta Dermato-venereologica, vol. 91, n. 5, settembre 2011, pp. 600–1, DOI:10.2340/00015555-1132, PMID 21597677. URL consultato il 14 ottobre 2014.

oadoi.org

Higa F, Shinzato T, Toyama M, Haranaga S, Furugen M, Tateyama M, Kawakami K, Saito A, Efficacy of pazufloxacin mesilate in Legionnaires' disease: a case report and in vitro study of the isolate, in Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, vol. 11, n. 3, giugno 2005, pp. 164–8, DOI:10.1007/s10156-005-0381-3, PMID 15990982. URL consultato il 14 ottobre 2014.
Takahashi K, Muratani T, Akasaka S, Yamada Y, Matsumoto T, The efficacy of sequential therapy using pazufloxacin followed by oral fluoroquinolones for treatment of pyelonephritis, in Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, vol. 19, n. 3, giugno 2013, pp. 456–64, DOI:10.1007/s10156-012-0505-5, PMID 23188166. URL consultato il 14 ottobre 2014.
Hamada Y, Imaizumi H, Kobayashi M, Sunakawa K, Saigenji K, Yago K, Liver abscess that responded well to pazufloxacin therapy, in Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, vol. 12, n. 1, febbraio 2006, pp. 42–6, DOI:10.1007/s10156-005-0423-x, PMID 16506089. URL consultato il 14 ottobre 2014.

oxfordjournals.org

jac.oxfordjournals.org

Higa F, Akamine M, Haranaga S, Tohyama M, Shinzato T, Tateyama M, Koide M, Saito A, Fujita J, In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species, in The Journal of Antimicrobial Chemotherapy, vol. 56, n. 6, dicembre 2005, pp. 1053–7, DOI:10.1093/jac/dki391, PMID 16260445. URL consultato il 14 ottobre 2014.